2020
Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma
Gong Y, Fan Z, Luo G, Huang Q, Qian Y, Cheng H, Jin K, Ni Q, Yu X, Liu C. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Pancreatology 2020, 20: 716-721. PMID: 32249060, DOI: 10.1016/j.pan.2020.02.016.Peer-Reviewed Original ResearchConceptsHistory of APPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma patientsLog-rank testAcute pancreatitisSurgical resectionDuctal adenocarcinomaPoor survivalHazard ratioHistory of acute pancreatitisDiagnosis of pancreatic ductal adenocarcinomaAssociated with poor survivalIndependent survival predictorMultivariable-adjusted hazard ratiosKaplan-Meier methodRetrospective cohort studyCox proportional hazards modelsProportional hazards modelOverall survivalRemote historyClinical characteristicsCohort studyMultivariate analysisRisk factors
2013
Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
Liu C, Chien Y, Hsieh M, Hwang T, Hwu H, Liu C. Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis. Journal Of Clinical Psychopharmacology 2013, 33: 18-23. PMID: 23277261, DOI: 10.1097/jcp.0b013e31827cb017.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisUltra-high riskFirst-episode psychosis patientsDrug-naiveUltra-high risk stateUltra-high-risk patientsLow-dose aripiprazoleNegative symptom scoresPositive symptom scoresFlexible dosing strategyState of psychosisTreatment responseAntipsychotic therapyDrug-naive populationSevere psychopathologyUHR patientsFirst-episodeAripiprazoleAdverse eventsSymptom scoresPsychosisRisk stateConcomitant medicationsTarget doseClinical improvement
2012
CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survivalZotepine-related myopathy in a patient with schizophrenia
Chen I, Hsieh M, Hwang T, Liu C. Zotepine-related myopathy in a patient with schizophrenia. European Journal Of Clinical Pharmacology 2012, 69: 725-726. PMID: 22797903, DOI: 10.1007/s00228-012-1346-y.Peer-Reviewed Original Research
2006
Familial Aggregation of Insulin Resistance in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease
Abdelmalek M, Liu C, Shuster J, Nelson D, Asal N. Familial Aggregation of Insulin Resistance in First-Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology And Hepatology 2006, 4: 1162-1169. PMID: 16901766, DOI: 10.1016/j.cgh.2006.06.001.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFirst-degree relativesFatty liver diseaseCryptogenic cirrhosisDiabetes mellitusLiver diseaseGenetic predispositionRisk of DMFamilial clusteringFirst-degree family membersBody mass indexInsulin resistance syndromeSignificant survival differenceExpression of IRWarrants further investigationNAFLD patientsMass indexResistance syndromeInsulin resistanceMedical historySurvival differencesHealthy controlsCardiac diseaseRenal stonesFamilial aggregation studies
2004
One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplant